TLSI — TriSalus Life Sciences Cashflow Statement
0.000.00%
Last trade - 00:00- $259.94m
- $272.63m
- $45.15m
Annual cashflow statement for TriSalus Life Sciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | C2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -28.8 | -47.2 | -59.4 | -30 | -39.2 |
| Depreciation | |||||
| Non-Cash Items | 5.82 | 12.2 | 7.56 | -1.99 | 18.5 |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.131 | 2.3 | 0.537 | -9.55 | 2.07 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -22.7 | -32.3 | -50.6 | -40.8 | -18 |
| Capital Expenditures | -1.1 | -0.655 | -0.588 | -0.345 | -0.918 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -1.16 | -1.13 | -1 | 0 | 0.08 |
| Sale of Fixed Assets | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -2.26 | -1.79 | -1.59 | -0.345 | -0.838 |
| Financing Cash Flow Items | 0.117 | 0 | 45.4 | -2.59 | -2.07 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 50.8 | 13.5 | 54.6 | 37.9 | 30.8 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 25.8 | -20.6 | 2.46 | -3.25 | 11.9 |